Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by BRISTOL MYERS SQUIBB
Farletuzumab ecteribulin is an antibody drug conjugate made of a humanized IgG1 antibody against folate receptor alpha, linked by a cathepsin B-cleavable linker to the microtubule inhibitor eribulin. After binding and internalization by FRA-expressing cells, eribulin is released, inhibits tubulin polymerization and causes G2/M arrest and tumor cell death. It is studied in ovarian neoplasms.
Summary written with AI from the sources listed at the end of this page.
Neoplasms, Ovarian
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.
See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMY catalysts and pipeline →